FLGT Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
FLGT is not a good immediate buy for a Beginner with a long-term horizon and $50,000-$100,000 to invest. The stock has some long-term turnaround potential, but right now the setup is mixed-to-bearish: technicals are weak, hedge funds are selling, analyst targets were cut, and the next earnings report is a near-term binary event. Since the user is impatient and unwilling to wait for a better entry, I would not buy here; I would hold and wait for stronger confirmation.
The trend is currently weak. MACD histogram is slightly negative and still expanding lower, RSI_6 at 39.17 shows soft momentum but not oversold, and the moving averages are bearish with SMA_200 > SMA_20 > SMA_5. Price at 15.21 is just above support at 14.914 and below pivot resistance at 15.642, which suggests the stock is still trading in a fragile range rather than starting a confirmed uptrend.
["Fulgent expects 2026 revenue growth of about 53% driven by acquisitions of Bako and StrataDx.", "The company has historically beaten EPS estimates 100% of the time over the past two years.", "Q4 2025 revenue grew 9.34% year over year, showing a return to top-line growth.", "Options positioning is bullish with low put-call ratios, suggesting traders are leaning positive.", "No significant insider selling was reported over the last month."]
["UBS cut its price target to $22 from $35, showing reduced near-term optimism.", "There have been no upward EPS revisions in the last three months, and revenue estimates saw two downward revisions.", "Hedge funds are selling, with selling activity up 169.46% last quarter.", "Q1 earnings are expected pre-market on May 1 with an estimated EPS of -$0.35 and revenue down 7.4% year over year.", "Technical trend remains bearish with negative MACD and weak moving averages."]
In the latest reported quarter, 2025/Q4, revenue increased to $83.34M, up 9.34% year over year, which is a positive growth signal. But profitability remains weak: net income was -$23.42M and EPS was -0.76, even though both improved sharply year over year from a worse base. Gross margin fell to 36.67%, down 6.41 points year over year. For the upcoming Q1 2026 season, the company is expected to report pre-market on May 1 with estimated EPS of -$0.35 and revenue of $68.09M, implying a 7.4% revenue decline year over year.
The latest analyst trend is negative on expectations: UBS lowered its price target to $22 from $35 while keeping a Buy rating. That is still constructive on direction, but the target cut shows analysts are less confident than before. Wall Street’s pros view is mixed: the Buy rating and long-term growth story are positives, but the lower target, lack of upward estimate revisions, and revenue estimate cuts show caution. Net: the Street is positive in rating, but less enthusiastic in price expectations.
